The University of Galway has appointed Professor Peter Doran as the new Director of its new clinical trials institute, which it says will transform the University’s ability to evaluate cutting-edge clinical treatments, medical diagnostics and preventative therapies.
University President, Professor Ciarán Ó hÓgartaigh, said, “As a cornerstone of our research architecture, this institute led by Professor Doran, will give further impetus and focus to translating our research discoveries from the lab-bench to the bedside and builds on our considerable strengths in Medical Technologies and Advanced Therapies.”
Professor Peter Doran said, “The development of the clinical trials institute at the University of Galway will have impact locally, nationally and globally. Our research programme will tackle the major health issues facing society today and into the future. By developing and growing linkages with our clinical partners in Saolta, with Community Health Organisation Area 2 and with industry we will ensure that today’s health research becomes tomorrow’s healthcare. We will leverage our current expertise and experience to ensure Galway is the national lead in clinical research.”
Professor Doran leads a significant biomarker research programme and has established a high throughput biomarker validation laboratory, which is contributing to major national and international end organ damage biomarker studies, reflecting his research interests in the molecular drivers of organ damage, biomarker discovery and translation to practice.
In addition, he established the graduate taught programme in clinical and translational research which includes a suite of programmes designed to address the career stage specific education and training requirements of clinical research personnel.
Professor Doran has also served as Associate Dean for Research at the UCD School of Medicine, Vice-Principal for Research at the UCD College of Health & Agricultural Science and Director of the Ireland East Hospital Group research network.